Michelle Peters
Acute Care · Tulsa, OKNPI 1306255138
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,041 and has fallen 98.7% since, to $26 in 2025.
Across 188 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$716
- Boehringer Ingelheim$465
- AstraZeneca$459
- Actelion Pharmaceuticals US, Inc.$422
- GSK$311
- Sanofi$168
- plus $910 from 17 others
What the payments were for
- Food & beverage$3,451100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 38 | $716 |
| Boehringer Ingelheim | 29 | $465 |
| AstraZeneca(2 entities) | 23 | $459 |
| Actelion Pharmaceuticals US, Inc. | 18 | $422 |
| GSK | 27 | $311 |
| Sanofi | 4 | $168 |
| Baxter Healthcare | 7 | $156 |
| Electromed, Inc. | 10 | $151 |
| Amgen | 6 | $137 |
| AbbVie | 7 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Inogen, Inc. | 4 | $43 |
| Covis Pharma GmbH | 2 | $40 |
| Intuitive Surgical | 1 | $30 |
| Abiomed | 1 | $26 |
| Genentech USA, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Merck | 1 | $16 |
| Chiesi USA, Inc. | 1 | $14 |
How this compares
$3,451 in reported general payments places this provider in the 80th percentile of 266 acute care providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $34,249 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $22,928 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,644 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $9,281 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,578 |
| Montelukast Sodium | 21 | $392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $311 | $34,24933 claims |
| AstraZenecaBreztri Aerosphere | $459 | $22,92826 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $465 | $18,92433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 266 acute care providers in Oklahoma.
Other acute care in Tulsa
- Pavel BuzadzhiTulsa$26K
- Jerrie MoralesTulsa$15K
- Lisa ArmstrongTulsa$14K
- Ganna StarkeyTulsa$14K
- Jasmine ThompsonTulsa$12K
- Christina HulseyTulsa$9K
- Brandon KingTulsa$9K
- Christina OverlyTulsa$8K
- Brian HutchinsonTulsa$7K
- Mallory NealTulsa$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.